About: AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Sector: Healthcare
Industry: Biotechnology
Latest price: $11.10 (+5.41%)
AGMB NASDAQ AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV American Depositary Shares share price
AGMB price activity
Último preço
$ 11,100
Variação (24h)
0,57 USD (5,41%)
Volume
133.70K
Volume (média 4 sem.)
-
Abertura
$ 10,62
Variação do dia
$ 10,58 - $ 11,35
Fechamento anterior
$ 10,53
Último negócio
30 Sep, 8:00 pm GMT+0
Atrasado
30 Sep, 8:00 pm GMT+0
AGMB price performance
Atrasado
30 Sep, 8:00 pm GMT+0
quote.marketSignals